FDA
-
-
-
-
-
-
-
Mesoblast names Facchina as new chair, Bell to stay as director
-
-
-
-
-
-
-
Mesoblast to Meet With FDA Next Month to Discuss Rexlemestrocel-L and Opioid Cessation
-
-
-
-
-
-
-
Banner Year for Mesoblast With First FDA Product Approval and Successful Commercial Launch of Ryoncil®
-
-
-
-
-
-
-
Mesoblast Appoints Corporate Finance Leader Lyn Cobley To Board
-
-
-
-
-
-
-
Mesoblast Financial Results and Corporate Update Webcast
-
-
-
-
-
-
-
Revascor Improves Survival and Reduces Major Morbidity in High-Risk Ischemic Heart Failure Patients With Inflammation
-
-
-
-
-
-
-
Patient Enrollment Commenced in Pivotal Phase 3 Trial of Rexlemestrocel-L for Chronic Low Back Pain
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

